

**BIOAVAILABILITY ENHANCEMENT OF DRUGS
THROUGH STRATUM CORNEUM BY USING
NATURAL PENETRATION ENHANCERS VIZ. *B.*
LANZAN AND *S. CHINESIS***

A

Thesis

**Submitted for the Award of the Ph.D. degree of
PACIFIC ACADEMY OF HIGHER EDUCATION AND
RESEARCH UNIVERSITY**

By

SURYAVANSHI KIRAN ARUN

Under the Supervision of

Dr. A. VENKATCHALAM

Professor
Pacific College of Pharmacy
Pacific Academy of Higher Education and
Research University, Udaipur

Dr. YOGESH VISHNUPANT USHIR

Principal
S.M.B.T. College of Pharmacy, Dhamangaon, Tal.
Igatpuri, Nashik, Maharashtra



**FACULTY OF PHARMACY
PACIFIC ACADEMY OF HIGHER EDUCATION AND
RESEARCH UNIVERSITY, UDAIPUR**

2024

DECLARATION

I, **Mr. SURYAVANSHI KIRAN ARUN S/o Mr. ARUN KAUTIK SURYAVANSHI** resident of Audumbar, Bungalow No. D-1, Sai Shraddha Bungalows, Opp. Sai Simaran Row Houses, Narhari Nagar, Pathardi Phata, Nashik - 422010, Maharashtra, hereby declare that the research work incorporated in the present thesis entitled **“BIOAVAILABILITY ENHANCEMENT OF DRUGS THROUGH STRATUM CORNEUM BY USING NATURAL PENETRATION ENHANCERS VIZ. B. LANZAN AND S. CHINESIS”** is our original work. This work (in part or in full) has not been submitted to any University for the award or a Degree or a Diploma. I have properly acknowledged the material collected from secondary sources wherever required. I solely own the responsibility for the originality of the entire content.

Date: / /2024

(**SURYAVANSHI KIRAN ARUN**)

Signature of the Candidate

CERTIFICATE

It gives me immense pleasure in certifying that the thesis entitled “**BIOAVAILABILITY ENHANCEMENT OF DRUGS THROUGH STRATUM CORNEUM BY USING NATURAL PENETRATION ENHANCERS VIZ. B. LANZAN AND S. CHINESIS**” and submitted by **Mr. SURYAVANSHI KIRAN ARUN** is based on the work research carried out under my guidance. He has completed the following requirements as per Ph.D. regulations of the University;

- i. Course work as per University rules.
- ii. Residential requirements of the University.
- iii. Regularly presented Half Yearly Progress Report as prescribed by the University.
- iv. Published/ accepted minimum of two research paper in a refereed research journal.

I recommend the submission of thesis as prescribed/ notified by the University.

Date: / /2024

Dr. A. VENKATCHALAM

Professor
Pacific College of Pharmacy
Pacific Academy of Higher Education and Research University,
Udaipur

CERTIFICATE

It gives me immense pleasure in certifying that the thesis “**BIOAVAILABILITY ENHANCEMENT OF DRUGS THROUGH STRATUM CORNEUM BY USING NATURAL PENETRATION ENHANCERS VIZ. B. LANZAN AND S. CHINESIS**” and submitted by **Mr. SURYAVANSHI KIRAN ARUN** is based on the work research carried out under my guidance. He has completed the following requirements as per Ph.D. regulations of the University;

- i. Course work as per University rules.
- ii. Residential requirements of the University.
- iii. Regularly presented Half Yearly Progress Report as prescribed by the University.
- iv. Published/ accepted minimum of two research paper in a refereed research journal.

I recommend the submission of thesis as prescribed/ notified by the University.

Date: / /2024

Dr. YOGESH VISHNUPANT USHIR

Principal

S.M.B.T. College of Pharmacy, Dhamangaon,
Tal. Igatpuri, Nashik, Maharashtra

COPYRIGHT

I, **SURYAVANSHI KIRAN ARUN**, hereby declare that the Pacific Academy of Higher Education and Research University Udaipur, Rajasthan shall have the rights to preserve, use and disseminate this dissertation/thesis entitled **“BIOAVAILABILITY ENHANCEMENT OF DRUGS THROUGH STRATUM CORNEUM BY USING NATURAL PENETRATION ENHANCERS VIZ. B. LANZAN AND S. CHINESIS”** in print or electronic format for academic/research purpose.

Date: / /2024

SURYAVANSHI KIRAN ARUN

Place: Udaipur

ACKNOWLEDGEMENT

First of all I thank Almighty for giving me the opportunity to carry myself forward in the path of my dream with all blessings and making me the best out of me. My life's most awaited, proud moment, submission of Ph.D. thesis which I dreamt for years and years is now a reality. This would have not been possible without the help of many seen and unseen helping hands. I owe my gratitude to all those people who have made this dissertation possible.

I would like to express my sincere gratitude to my research guide **Dr. A. VENKATCHALAM**, Professor, Pacific University Udaipur, Rajasthan for the continuous support of my Ph.D. study. This work would not have been possible without his guidance, support and encouragement. Under his guidance I successfully overcame many difficulties and learned a lot.

At this moment of achievement, first of all I pay reverence to my Co-guide **Dr. YOGESH VISHNUPANT USHIR**, Principal, S.M.B.T. College of Pharmacy, Dhamangaon, Tal. Igatpuri, Nashik, Maharashtra and related research, for his critical remarks, precise discussions, timely suggestion and immense motivation. His guidance helped me in all the time of research and writing of this thesis. I could not have imagined having a better advisor and mentor for my Ph.D. study. His unflinching courage and conviction will always inspire me, and I hope to continue to work with his noble thoughts.

I thank **Mr Kundan J. Tiwari**, HOD, SMBT Institute of diploma pharmacy, Dhamangaon Nashik, Maharashtra and non-teaching staff of SMBT Institute of diploma pharmacy, for their support in research labs.

I express my sincere gratitude and indebtedness to **Prof. (Dr.) HEMANT KOTHARI**, Dean, Pacific Academy of Higher Education and Research University, Udaipur, Rajasthan, India, for providing me with the necessary facilities.

I warmly thank **Dr. RAJESH KANJA**, Assistant Professor (IT- Manager), for his valuable advice, and Motivation throughout my work.

I gratefully acknowledge **Mr. RAMESH AGARWAL**, for his understanding, encouragement and personal devotion which have provided good and smooth basis for my Ph.D. tenure.

I would like to extend my sincere thanks to the management of Pacific Academy of Higher Education and Research, Udaipur for permitting me to carry out my research work and all the teaching and non-teaching staffs of PAHER for their constant support and cooperation. I would like to thank all whose direct and indirect support helped me in completing my thesis in time.

Last but not least, I would like to pay high regards to my Mother **Mrs. Ratna Arun Suryavanshi** and Father **Mr. Arun Kautik Suryavanshi**, sister **Mrs. Leena Anand Sonawane**, Brother in law **Mr. Anand Sonawane** and my loving daughter **Aaradhya Kiran Suryavanshi**, and my dear students, for their sincere encouragement and inspiration throughout my research work and lifting me uphill this phase of life. I owe everything to them. Besides this, several people have knowingly and unknowingly helped me in the successful completion of this project. I owe my deepest gratitude towards my wife **Mrs. Vrushali K. Suryavanshi** for her endless support and understanding of my goals and aspirations.

My distinctive thanks to *M/s Shorya Thesis Printers & Binders, Udaipur team* for their role in shaping the matter, creative design work and bringing out this document meticulously, neatly and timely.

Many apologies to anyone I have inadvertently missed mentioning.

SURYAVANSHI KIRAN ARUN

LIST OF TABLES

Sr. No.	Table No.	Title of Tables	Page No.
1.	1.1	Optimal medication characteristics and a few things to think about when preparing an oral drug delivery device	29
2.	5.1	List of variables employed in Regular 32 Design	77
3.	5.2	Composition of gel on the Basis of Regular 3 ² Design	79
4.	5.3	Composition of optimized gel formulation	80
5.	5.4	Composition of different gel base	81
6.	5.5	Skin irritation score	82
7.	5.6	Formulations for diffusion study	84
8.	6.1	Organoleptic property of <i>Buchananialanzan</i> and <i>Simmondiachinesis</i>	94
9.	6.2	Calibration curve of the proposed method for the estimation of colchicine	95
10.	6.3	Statistical parameters correlated to standard curve of colchicine	96
11.	6.4	Major peaks observed in the FTIR spectrum of Colchicine	97
12.	6.5	Major peaks observed in the FTIR spectrum of Carbopol	98
13.	6.6	Estimation of total ash in <i>BLO and SCO</i>	102
14.	6.7	Physicochemical Evaluation of BLO and SCO	102
15.	6.8	Clinical observation of oils	103
16.	6.9	Comparative data of Preformulation studies	104

17.	6.10	pH values of gel formulations containing <i>Buchananialanzan</i> oil	106
18.	6.11	pH values of gel formulations containing <i>Simmondsiachinesis</i> oil	107
19.	6.12	Spread ability values of gel formulations containing <i>Buchananialanzan</i> oil	108
20.	6.13	Spreadability values of gel formulations containing <i>Simmondsiachinesis</i> oil	109
21.	6.14	Drug content values of gel formulations containing <i>Buchananialanzan</i> oil	110
22.	6.15	Drug content values of gel formulations containing <i>Simmondsiachinesis</i> oil	110
23.	6.16	Skin irritation study of gel formulations containing <i>Buchananialanzan</i> oil	111
24.	6.17	Skin irritation study of gel formulations containing <i>Simmondsiachinesis</i> oil	111
25.	6.18	<i>In-vitro</i> drug release data for optimization of BL4	132
26.	6.19	<i>In-vitro</i> drug release data for optimization of BL5	136
27.	6.20	Log cumulative drug remaining data for BL5	140
28.	6.21	Cumulative drug release data for BL5 wrt to SQRT	141
29.	6.22	Log cumulative drug released data for BL5 wrt Log time	142
30.	6.23	<i>In-vitro</i> drug release data for optimization of BL5	143
31.	6.24	<i>In-vitro</i> drug remain data for BL5	146
32.	6.25	<i>In-vitro</i> drug release data for optimization of BL6	150
33.	6.26	<i>In-vitro</i> drug remain data for BL6	155
34.	6.27	Cumulative % drug release data wrt to Time	158
35.	6.28	Log cum % drug release wrt to Time	159

36.	6.29	Cumulative % drug released data wrt to SQRT	160
37.	6.30	Log cumulative % drug released wrt to log time	161
38.	6.31	<i>In-vitro</i> drug release data for optimization of SCO4	162
39.	6.32	<i>In-vitro</i> drug remain data for SCO4	166
40.	6.33	<i>In-vitro</i> drug release data for optimization of SCO5	170
41.	6.34	<i>In-vitro</i> drug remaining data for SCO5	174
42.	6.35	<i>In-vitro</i> drug release data for optimization of SCO6	176
43.	6.36	<i>In-vitro</i> drug remaining data for SCO6	180
44.	6.37	Cumulative % drug release wrt to time	183
45.	6.38	Log cumulative % drug remaining wrt to Time	184
46.	6.39	Cumulative % drug released wrt to SQRT	185
47.	6.40	Log cumulative % drug released wrt log time	186
48.	6.41	<i>In-vitro</i> drug release data for optimization of BL4 (through snake skin)	187
49.	6.42	<i>In-vitro</i> drug remain data for BL4 (through snake skin)	191
50.	6.43	<i>In-vitro</i> drug release data for optimization of BL5	193
51.	6.44	<i>In-vitro</i> drug remain data for BL5	197
52.	6.45	<i>In-vitro</i> drug remain data for BL5	199
53.	6.46	<i>In-vitro</i> drug remain data for BL6	203
54.	6.47	Cumulative % drug released wrt Time	205
55.	6.48	Log cumulative % drug remaining wrt to Time	206
56.	6.49	Cumulative % drug released wrt to SQRT	207
57.	6.50	Log cumulative % drug released wrt to Log time	208
58.	6.51	<i>In-vitro</i> drug release data for optimization of SCO4	209
59.	6.52	<i>In-vitro</i> drug remain data for SCO4	213
60.	6.53	<i>In-vitro</i> drug release data for optimization of SCO5	215

61.	6.54	<i>In-vitro</i> drug remain data for SCO5	219
62.	6.55	<i>In-vitro</i> drug release data for optimization of SCO6	221
63.	6.56	<i>In-vitro</i> drug remain data for SCO6	225
64.	6.57	Pharmacokinetic parameters of Optimized formulations	230
65.	6.58	AUC of standard colchicine.	231
66.	6.59	AUC of BLO6	231
67.	6.60	AUC of SCO6	232

LIST OF FIGURES

Sr. No.	Figure No.	Title of Figures	Page No.
1.	1.1	Illustration of macroroutes of drug permeation across intact skin	02
2.	1.2	Conceivable micro ways for medicine infiltration crossways human membrane intracellular or Trans cellular	03
3.	1.3	Williamson ether synthesis process	17
4.	1.4	Carboxymethylation of natural gums	17
5.	1.5	Uric acid metabolism	21
6.	1.6	Different Parts of the Skin	26
7.	1.7	Transportation pathways enter the skin via the trans epidermal (A) and trans appendageal routes. Distribution through hair shafts and the sweat glands is part of the trans-appendageal pathway (B).	28
8.	1.8	Buchanania lanzan shrub and seed	39
9.	1.9	Jojoba <i>Simmondsia chinensis</i>	42
10.	1.10	MOA of NSAID	44
11.	5.1	Soxhlet apparatus	76
12.	5.2	Franz diffusion cell with goat skin	88
13.	6.1	Wavelength scan of Colchicine in PBS pH 7.5.	95
14.	6.2	Calibration curve of Colchicine in PBS (pH 7.4) at 350 nm	96
15.	6.3	FT-IR of Colchicine	97
16.	6.4	FT-IR of Carbopol	98
17.	6.5	FT-IR of BLO	99

18.	6.6	FT-IR of IPA	99
19.	6.7	FT-IR of PEG	100
20.	6.8	FT-IR of SCO	100
21.	6.9	FT-IR of TEA	101
22.	6.10	pH values of gel formulations containing <i>Buchananialanzan</i> oil	106
23.	6.11	pH values of gel formulations containing <i>Simmondsiachinesis</i> oil	107
24.	6.12	Spreadability values of gel formulations containing <i>Buchananialanzan</i> oil	108
25.	6.13	Spreadability values of gel formulations containing <i>Simmondsiachinesis</i> oil	109
26.	6.14	AFM-Carbopol control gel-without drug (F1)	112
27.	6.15	AFM-Carbopol control gel-without drug (F2)	113
28.	6.16	AFM-Carbopol control gel-without drug (F3)	113
29.	6.17	AFM-Carbopol gel (F1)	114
30.	6.18	AFM-Carbopol gel (F2)	115
31.	6.19	AFM-Carbopol gel (F3)	115
32.	6.20	Contact angle of Drop 1 and 5	116
33.	6.21	Contact angle of Drop 10 and 11	117
34.	6.22	Contact angle of Drop 8 and 9	117
35.	6.23	3D Image of BLO after 2 hrs	118
36.	6.24	Diagnostic analysis of BLO after 2 hrs	119
37.	6.25	ANOVA of BLO after 2 hrs	120
38.	6.26	Conour of BLO after 2 hrs	120
39.	6.27	3D Image of BLO after 5 hrs	121

40.	6.28	Diagnostic analysis of BLO after 5 hrs	121
41.	6.29	ANOVA of BLO after 5 hrs	122
42.	6.30	Conour of BLO after 5 hrs	122
43.	6.31	3D Image of BLO after 7 hrs	123
44.	6.32	Diagnostic analysis of BLO after 7 hrs	123
45.	6.33	ANOVA of BLO after 7 hrs	124
46.	6.34	Conour of BLO after 7 hrs	124
47.	6.35	3D Image of SCO after 2 hrs	125
48.	6.36	Diagnostic analysis of SCO after 2 hrs	125
49.	6.37	Conour of SCO after 2 hrs	126
50.	6.38	3D Image of SCO after 5 hrs	126
51.	6.39	Diagnostic analysis of SCO after 5 hrs	127
52.	6.40	ANOVA of SCO after 5 hrs	128
53.	6.41	Conour of SCO after 5 hrs	128
54.	6.42	3D Image of SCO after 7 hrs	129
55.	6.43	Diagnostic analysis of SCO after 7 hrs	129
56.	6.44	ANOVA of SCO after 7 hrs	130
57.	6.45	Contour of SCO after 7 hrs	130
58.	6.46	Log time vs log cumulative % drug release	133
59.	6.47	Time vs Cumulative % drug release	133
60.	6.48	Time vs Cumulative % drug release graph	134
61.	6.49	Time vs Log cumulative % drug release	134
62.	6.50	Time vs Drug remain	135
63.	6.51	Time vs Log cumulative % drug release	137
64.	6.52	Log time vs Log cumulative % drug released	137
65.	6.53	Time vs cumulative % drug release	138

66.	6.54	Time vs Cumulative % drug released	138
67.	6.55	Time vs Drug remained	139
68.	6.56	Time vs Log cumulative % drug remaining	140
69.	6.57	Sq root time vs Cumulative % drug release	141
70.	6.58	Log time vs log cumulative % drug released	142
71.	6.59	Log time vs Log cumulative % drug release	144
72.	6.60	Time vs Cumulative % drug release	144
73.	6.61	Sq root of time vs cumulative % drug released	145
74.	6.62	Time vs Log cumulative % drug remaining	145
75.	6.63	Time vs Log cumulative % drug remaining	147
76.	6.64	Log time vs Log cumulative % drug released	147
77.	6.65	Time vs cumulative % drug released	148
78.	6.66	Sq root of time vs cumulative % drug released	148
79.	6.67	Time vs cube root of drug remaining	149
80.	6.68	Log time vs log cumulative % drug release	151
81.	6.69	Time vs Cumulative % drug release	151
82.	6.70	Sq root time vs cumulative % drug release	152
83.	6.71	Time vs Log cumulative % drug remaining	152
84.	6.72	Time vs Cube root drug remaining	153
85.	6.73	Time vs cumulative % drug remaining	153
86.	6.74	Log time vs Log cumulative % drug released	154
87.	6.75	Time vs Cumulative % drug released	156
88.	6.76	Sq root time vs Cumulative % drug released	156
89.	6.77	Time vs Cube root of drug remain	157
90.	6.78	Time vs cumulative % drug released	158
91.	6.79	Time vs log cumulative % drug remaining.	159

92.	6.80	Sq root time vs cumulative % drug released	160
93.	6.81	Log time vs log cumulative % drug released	161
94.	6.82	Log time vs log cumulative % drug release	163
95.	6.83	Time vs cumulative % drug release	163
96.	6.84	Sq root time vs cumulative % drug released	164
97.	6.85	Time vs Log cumulative % drug remaining	164
98.	6.86	Time vs cube root drug remained	165
99.	6.87	Time vs log cumulative % drug remaining	167
100.	6.88	Log time vs <Log cumulative % drug released	167
101.	6.89	Time vs cumulative % drug released	168
102.	6.90	Sq root time vs cumulative % drug released	168
103.	6.91	Time vs cube root of drug remain	169
104.	6.92	Log time vs log cumulative % drug release	171
105.	6.93	Time vs cumulative % drug release	171
106.	6.94	Sq root time vs cumulative % drug released	172
107.	6.95	Time vs Log cumulative % drug remaining	172
108.	6.96	Time vs Cube root drug remain	173
109.	6.97	Time vs cube root drug remain.	175
110.	6.98	Log time vs Log cumulative % drug release	177
111.	6.99	Time vs Cumulative % drug release	177
112.	6.100	Sq root time vs cumulative % drug released	178
113.	6.101	Time vs log cumulative % drug remaining	178
114.	6.102	Time vs cube root drug remain	179
115.	6.103	Time vs cube root of drug remain	181
116.	6.104	Time vs cumulative % drug released	183
117.	6.105	Time vs log cumulative % drug remaining	184

118.	6.106	Sq root time vs cumulative % drug released	185
119.	6.107	Log time vs log cumulative % drug released	186
120.	6.108	Log time vs Log cumulative % drug release	188
121.	6.109	Time vs cumulative % drug release	188
122.	6.110	Sq root time vs cumulative % drug released	189
123.	6.111	Time vs log cumulative % drug remaining	189
124.	6.112	Time vs Cube root of drug remain	190
125.	6.113	Time vs Cube root of drug remain	192
126.	6.114	Log time vs log cumulative % drug release	194
127.	6.115	Time vs cumulative % drug release	194
128.	6.116	Sq root time vs cumulative % drug releasesd	195
129.	6.117	Time vs log cumulative % drug remaining	195
130.	6.118	Time vs cube root of drug remain	196
131.	6.119	Time vs cube root of drug release	198
132.	6.120	Log time vs log cumulative % drug release	200
133.	6.121	Time vs cumulative % drug release	200
134.	6.122	Sq root time vs cumulative % drug released	201
135.	6.123	Time vs log cumulative % drug remaining	201
136.	6.124	Time vs Cube root drug remain	202
137.	6.125	Time vs Cube root of drug remain	204
138.	6.126	Time vs cumulative % drug released	205
139.	6.127	Time vs log cumulative % drug remaining	206
140.	6.128	Sq root time vs cumulative % drug released	207
141.	6.129	Log time vs log cumulative % drug released	208
142.	6.130	Log time vs log cumulative % drug release	210
143.	6.131	Time vs cumulative % drug release	210

144.	6.132	Sq root time vs cumulative % drug relased	211
145.	6.133	Time vs log cumulative % drug remaining	211
146.	6.134	Time vs cube root of drug remain	212
147.	6.135	Time vs cube root of drug remain	214
148.	6.136	Log time vs log cumulative % drug release	216
149.	6.137	Time vs cumulative % drug release	216
150.	6.138	Sq root time vs Cumulative % drug released	217
151.	6.139	Time vs log cumulative % drug remaining	217
152.	6.140	Time vs cube root of drug remain	218
153.	6.141	Time vs cube root of drug remain	220
154.	6.142	Log time vs Log cumulative % drug release	222
155.	6.143	Time vs cumulative % drug release	222
156.	6.144	Sq root time vs cumulative % drug released	223
157.	6.145	Time vs log cumulative % drug remaining	223
158.	6.146	Time vs cube root of drug remain	224
159.	6.147	Time vs cube root of drug remain	226
160.	6.148	Time vs % Drug release through goat skin	227
161.	6.149	Time vs % drug released through snake skin	228
162.	6.150	<i>In-vivo</i> animal study by application of conlchicine gel	229
163.	6.151	<i>In- vivo</i> time vs concentration	232